Products must note that they can increase blood pressure, but boxed warnings about adverse cardiovascular events can be ...
Lipocine Inc. (NASDAQ: LPCN), a biopharmaceutical company leveraging its proprietary technology platform to augment therapeutics through effective oral delivery, today announced that the U.S. Food and ...
The U.S. Food and Drug Administration said on Friday it issued new labeling changes for testosterone products based on ...
The FDA has developed draft guidance addressing confusion and legal action over the naming and labeling of plant-based alternatives to eggs, ...
The inspection comes after a ProPublica investigation revealed that drugs made at the Glenmark Pharmaceuticals plant ...
The companies in question, Dr. Reddy’s Laboratories, Sun Pharma and Zydus Pharmaceuticals, are recalling seizure treatments, ...
Novartis receives third FDA approval for oral Fabhalta® (iptacopan) – the first and only treatment approved in C3 glomerulopathy (C3G) Fabhalta is the only oral alternative complement pathway ...
Lipocine (LPCN) announced that the FDA has recently informed sponsors of approved testosterone products about class-wide labeling changes. This decision follows the Agency’s review of the ...
The FDA is also requiring all labels to include product-specific information on increased blood pressure for testosterone products based on the results of ABPM studies. "We are excited about these ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results